CD59‐deficient bone marrow erythroid cells from rats treated with procarbazine and propyl‐nitrosourea have mutations in thePig‐agene

Authors:

Abstract
Procarbazine (PCZ) andN‐propyl‐N‐nitrosourea (PNU) are rodent mutagens and carcinogens. Both induce GPI‐anchored marker‐deficient mutant‐phenotype red blood cells (RBCs) in the flow cytometry‐based rat RBCPig‐aassay. In the present study, we traced the origin of the RBC mutant phenotype by analyzingPig‐amutations in the precursors of RBCs, bone marrow erythroid cells (BMEs). Rats were exposed to a total of 450 mg/kg PCZ hydrochloride or 300 mg/kg PNU, and bone marrow was collected 2, 7, and 10 weeks later. Using a flow cell sorter, we isolated CD59‐deficient mutant‐phenotype BMEs from PCZ‐ and PNU‐treated rats and examined their endogenous X‐linkedPig‐agene by next generation sequencing.Pig‐amutations consistent with the properties of PCZ and PNU were found in sorted mutant‐phenotype BMEs. PCZ induced mainly A > T transversions with the mutated A on the nontranscribed strand of thePig‐agene, while PNU induced mainly T > A transversions with the mutated T on the nontranscribed strand. The treatment‐induced mutations were distributed across the protein coding sequence of thePig‐agene. The causal relationship between BMEs and RBCs and the agent‐specific mutational spectra in CD59‐deicient BMEs indicate that the rat RBCPig‐aassay, scoring CD59‐deficient mutant‐phenotype RBCs in peripheral blood, detectsPig‐agene mutation.
Funding Information
  • U.S. Food and Drug Administration

This publication has 40 references indexed in Scilit: